Clinical trials: Neoplasms, Pharyngeal
Squamous Cell Carcinoma of Head and Neck, Sinus Cancer
A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)
The purpose of this study to find out whether sacituzumab govitecan in combination with cetuximab is an effective and safe treatment approach for people with recurrent and/or metastatic head and neck squamous cell cancer (HNSCC).
- Conditions
- Squamous Cell Carcinoma of Head and Neck, Sinus Cancer, Nasal Cavity Cancer, Oral Cavity Cancer
- Trial name
- NCT07063212
- Testing
- Sacituzumab Govitecan, Cetuximab
- Where
- 7 sites in United States
- Volunteers
- 40 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
HNSCC, Lip SCC
Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
This is a prospective, multi-center, open-label, non-randomized, multi-arm phase II trial to evaluate the efficacy of combination therapy with pembrolizumab and cetuximab for patients with recurrent/metastatic HNSCC.
- Conditions
- HNSCC, Lip SCC, Oral Cavity Cancer, Oropharynx Cancer
- Trial name
- NCT03082534
- Testing
- Pembrolizumab, Cetuximab
- Where
- 4 sites in United States
- Volunteers
- 78 people
- Sponsor
- University of California, San Diego
Oropharynx Cancer, Oral Cavity
Oncology, Undernutrition and Sensoriality: Links, Mechanisms and Levers for Action
Cancers of the upper aerodigestive tract account for around 4% of all malignant tumours worldwide. Colon and liver cancer are the most common digestive cancers.
- Conditions
- Oropharynx Cancer, Oral Cavity, Colon Cancer, Liver Cancer
- Trial name
- ONDES (NCT06600295)
- Testing
- tests/questionnaires, biological samples, evaluation
- Where
- France
- Volunteers
- 306 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Nasopharyngeal Carcinoma, Oral Mucositis
Prospective Observational Study to Predict Severe Oral Mucositis Associated With Chemoradiotherapy in Nasopharyngeal Carcinoma Based on Deep Learning
The goal of this observational study is to apply the CNN-based DL method to extract the three-dimensional spatial information of IMRT dose distribution to predict the occurrence probability of serious radiotherapy and…
- Trial name
- NCT06032767
- Testing
- observational group
- Where
- China
- Volunteers
- 480 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Neoplasms, Salivary Gland Diseases
A Phase II Clinical Trial on Comparison of Effectiveness and Safeness of Different Amifostine Regimens
RATIONALE Radiotherapy is the primary therapeutic strategy for nasopharyngeal carcinoma. Radiotherapy may cause adverse effect such as xerostomia and mucositis.
- Conditions
- Nasopharyngeal Neoplasms, Salivary Gland Diseases, Bone Marrow Diseases, Mucositis
- Trial name
- NCT01762514
- Testing
- Amifostine every-other-day regimen, Amifostine everyday regimen
- Where
- 7 sites in China
- Volunteers
- 360 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
A Phase II Clinical Trial of Chemotherapy With or Without Endostar® Continuous Intravenous Infusion in Refractory NPC
We define refractory nasopharyngeal carcinoma as the following: recurrence with radiation brain injury after radiotherapy, recurrence after the second or more courses of radiotherapy, standard treatment failure after recurrence…
- Trial name
- NCT02590133
- Testing
- Recombinant Human Endostatin Injection (Endostar), Fluorouracil (5-Fu), Nedaplatin
- Where
- China
- Volunteers
- 328 people
- Sponsor
- Yun-fei Xia
Oropharyngeal Carcinoma
Off-line Adaptive Proton Therapy
This prospective in-silico study evaluates a novel Off-line Adaptive Proton Therapy (o-APT) workflow for patients with oropharyngeal cancer receiving proton therapy.
- Trial name
- o-APT (NCT07866547)
- Testing
- Off-line Adaptive Proton Therapy (o-APT) Workflow Evaluation
- Where
- Netherlands
- Volunteers
- 100 people
- Sponsor
- University Medical Center Groningen
Nasopharyngeal Carcinoma
The Efficacy of Camrelizumab Plus Stereotactic Body Radiotherapy in R/M NPC
Camrelizumab is an antibody targeting programmed death receptor 1 (PD-1) and its ligand programmed death-ligand 1 (PD- L1) that is designed to boost the immune system. It does this by allowing immune cells to fight the cancer.
- Trial name
- NCT04830267
- Testing
- Camrelizumab, Stereotactic body radiotherapy
- Where
- 3 sites in China
- Volunteers
- 39 people
- Sponsor
- Chongqing University Cancer Hospital
Oropharynx Cancer, Oropharynx Squamous Cell Carcinoma
Quality of Life After Primary TORS vs IMRT for Patients With Early-stage Oropharyngeal Squamous Cell Carcinoma
Oropharyngeal squamous cell carcinoma (OPSCC) is now the most frequently diagnosed head and neck cancer in Denmark which is mainly due to the increase of Human Papillomavirus (HPV).
- Conditions
- Oropharynx Cancer, Oropharynx Squamous Cell Carcinoma, Carcinoma, Squamous Cell, Carcinoma
- Trial name
- QoLATI (NCT04124198)
- Testing
- Intensity-Modulated Radiation Therapy (IMRT), Cisplatin, Nimorazole.
- Where
- 3 sites in Denmark
- Volunteers
- 138 people
- Sponsor
- Christian von Buchwald
Nasopharyngeal Carcinoma
Platinum Plus Low-dose Long-term Continuous Intravenous Infused 5-Fluorouracil in Recurrent Nasopharyngeal Carcinoma
Local control rates of nasopharyngeal carcinoma are increasing, but 15% of patients still have local recurrence within 5 years after initial treatment.
- Trial name
- NCT04764149
- Where
- China
- Volunteers
- 801 people
- Sponsor
- Sun Yat-sen University
Head and Neck Neoplasms
Definitive Chemo-Radiotherapy for Regionally Advanced Head and Neck Cancer With or Without Up-front Neck Dissection
Treatment of regionally-advanced head and neck squamous cell carcinoma (HNSCC) requires a multidisciplinary approach with a combination of surgery, radiotherapy (RT) and chemotherapy.
- Trial name
- UPFRONT-NECK (NCT02918955)
- Testing
- up-front neck dissection, radiotherapy, Chemotherapy (Cisplatin)
- Where
- 2 sites in Switzerland
- Volunteers
- 65 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Oropharyngeal Dysphagia
Autologous Muscle Derived Cells for Treatment of Tongue Dysphagia
The primary objective of this double-blind, randomized, placebo-controlled, multicenter clinical trial is to evaluate the safety of AMDC-GIR during the 24 months following 2 consecutive treatments of tongue dysphagia in male and…
- Trial name
- REVIVE (NCT05421689)
- Testing
- Autologous Muscle Derived Cells for Gastro-Intestinal Repair (AMDC-GIR)
- Where
- 2 sites in United States
- Volunteers
- 66 people
- Sponsor
- University of California, Davis
Nasopharyngeal Carcinoma
Intermittent Oral-esophageal Tube in Delayed Dysphagia After Radiotherapy for Nasopharyngeal Carcinoma
This is a prospective multicenter study with patients with delayed dysphagia after radiotherapy for NPC. Patients enrolled are randomly divided equally into the observation group and the control group.
- Trial name
- NCT06248840
- Testing
- Intermittent Oral-esophageal Tube Feeding, nasogastric tube feeding
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Zeng Changhao
Oropharynx Cancer, Oral Cancer
Very Intense Radiotherapy-chemotherapy Regimen in Advanced HNSCC
Altered fractionated radiotherapy and concomitant radio-chemotherapy have been shown to be two possibilities for improving efficacy of radiotherapy in locally advanced head and neck carcinomas.
- Conditions
- Oropharynx Cancer, Oral Cancer, Hypopharynx Cancer, Larynx Cancer
- Trial name
- NCT00162708
- Testing
- Radiotherapy 62-64 Gy in 5 W (31-32 f. of 2 Gy BID), Radiotherapy 62-64 Gy in 22-23 D (31-32 f of 2 Gy BID), CDDP, 5 Fu
- Where
- 3 sites in France
- Volunteers
- 120 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Oral Cavity Cancer, Oropharynx Cancer
The ENHANCE Study: Exercise and Nutrition in Head And Neck CancEr Survivors
The purpose of the study is to design a physical activity and dietary intervention for head and neck cancer patients.
- Conditions
- Oral Cavity Cancer, Oropharynx Cancer, Hypopharynx Cancer, Larynx Cancer
- Trial name
- NCT05798780
- Testing
- ENHANCE Intervention - Exercise and Nutrition, ENHANCE Intervention - Nutrition Only
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Hypopharyngeal Cancer
Efficacy and Safety of Toripalimab Combined With AP-induced Chemotherapy Followed in Non-metastatic IVB Hypopharyngeal Cancer
The goal of this type of study: single center exploratory clinical trial is to evaluate the efficacy and safety of Toripalimab combined with AP-induced chemotherapy followed by concurrent chemoradiotherapy and…
- Trial name
- NCT05860335
- Testing
- Cisplatin/Nedaplatin, albumin paclitaxel
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chinese PLA General Hospital
Nasopharyngeal Carcinoma, Neoplasm Metastasis
Hepatic Artery Infusion Pump for NPC Liver Metastases
A retrospective clinical trial to study the safety and effectiveness of hepatic arterial infusion (HAI) in treating patients who have nasopharyngeal carcinoma metastatic to the liver.
- Conditions
- Nasopharyngeal Carcinoma, Neoplasm Metastasis, Liver
- Trial name
- NCT03876574
- Testing
- DSA-guided implantation of hepatic artery infusion pump, Gemcitabine, Floxuridine
- Volunteers
- 16 people
- Sponsor
- Xiangya Hospital of Central South University
Nasopharyngeal Carcinoma (NPC), Solid Tumors
A Study of BL-M08D1 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma and Other Solid Tumors
This Phase Ib/II study is a clinical trial to evaluate the efficacy and safety of BL-M08D1 for Injection in patients with recurrent or metastatic nasopharyngeal carcinoma and other solid tumors.
- Trial name
- NCT07818486
- Testing
- BL-M08D1
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Nasopharyngeal Carcinoma
Screening for Early Diagnosis of Nose Cancer
The goal of this clinical trial is to evaluate the effectiveness of screening in identifying nasopharyngeal cancer (NPC), and evaluate the performance of Epstein-Barr virus (EBV) biomarkers in a community screening setting in…
- Trial name
- NCT07019870
- Testing
- EBV biomarker testing
- Where
- 2 sites in Singapore
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- National University Hospital, Singapore
Nasopharyngeal Carcinoma
Concurrent Chemotherapy for the Intermediate Risk Nasopharyngeal Carcinoma In Intensity-modulated Radiotherapy Era
Currently, concurrent chemoradiotherapy with/without sequential chemotherapy is the standard treatment modality for intermediate risk NPC (stage II and T3N0M0) according to the National Comprehensive Cancer Network guideline.
- Trial name
- NCT02633202
- Testing
- IMRT, Cisplatin
- Where
- China
- Volunteers
- 338 people
- Sponsor
- Sun Yat-sen University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.